Medical disorders that may account for sleep disturbance, especially delirium, Major
Depressive Disorder (DSMIV) and severe or significant acute or chronic pain.
Have acute or unstable medical conditions including renal failure, abnormal liver
function, cardiac arrhythmia, sitting blood pressure below 110/70 or above 140/100 or
postural blood drop 20 mm Hg.
Symptoms suggesting other sleep disorders (e.g., periodic limb movement disorder,
restless legs syndrome, obstructive sleep apnea syndrome), may be present but in the
opinion of the PI, do not account for the primary symptoms of insomnia.
Sleep disturbance symptoms that suggest a parasomnia. Parasomnias may include
behavioral manifestations of epileptiform activity or REM Behavior Disorder (RBD).
Previous treatment failure with quetiapine of AD-associated sleep disturbances, or
intolerance of quetiapine in a previous treatment trial.
Concomitant treatment with another antipsychotic or sedative-hypnotic medication,
Evidence of a major mental disorder other than dementia, such as major depression or
Stable doses (for 4 weeks prior to study entry) of antidepressant, antiepileptic mood
stabilizer, or acetylcholinesterase inhibitor medication will be allowed, but
initiation or recent changes in the dose of such medications will be prohibited.
Benzodiazepines within 2 weeks of study entry will not be allowed.